FDA Cross-Center Collaboration Act of 2016

1/11/2023, 1:32 PM

Congressional Summary of HR 5414

FDA Cross-Center Collaboration Act of 2016

This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to establish one or more Intercenter Institutes. Each institute must coordinate activities applicable to a major disease area among the FDA centers that review products. Activities may include coordinating staff with relevant expertise, streamlining product review, and enhancing interactions with patients, sponsors, and the biomedical community.

Current Status of Bill HR 5414

Bill HR 5414 is currently in the status of Bill Introduced since June 8, 2016. Bill HR 5414 was introduced during Congress 114 and was introduced to the House on June 8, 2016.  Bill HR 5414's most recent activity was Referred to the House Committee on Energy and Commerce. as of June 8, 2016

Bipartisan Support of Bill HR 5414

Total Number of Sponsors
1
Democrat Sponsors
0
Republican Sponsors
1
Unaffiliated Sponsors
0
Total Number of Cosponsors
1
Democrat Cosponsors
1
Republican Cosponsors
0
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill HR 5414

Primary Policy Focus

Health

Potential Impact Areas

Department of Health and Human ServicesDrug safety, medical device, and laboratory regulationExecutive agency funding and structureFood and Drug Administration (FDA)Government employee pay, benefits, personnel managementHealth promotion and preventive careMedical education

Alternate Title(s) of Bill HR 5414

FDA Cross-Center Collaboration Act of 2016To amend the Federal Food, Drug, and Cosmetic Act to provide for establishment of one or more Intercenter Institutes within the Food and Drug Administration for a major disease area or areas, and for other purposes.FDA Cross-Center Collaboration Act of 2016
Start holding our government accountable!

Comments